The Cooper Companies, Inc.
COOPER COMPANIES INC (Form: 10-Q, Received: 09/01/2017 16:22:01)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________
FORM 10-Q
_____________________________________________________________
ý
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For Quarterly Period Ended July 31, 2017
o
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from              to             
Commission File Number 1-8597
_____________________________________________________________
The Cooper Companies, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________
Delaware
94-2657368
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (925) 460-3600
_____________________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ý     No   o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   ý     No   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one).
Large accelerated filer
ý
 
Accelerated filer
o
Non-accelerated filer
o
(Do not check if a smaller reporting company)
Smaller reporting company
o
Emerging growth company
o
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes   o     No   ý
Indicate the number of shares outstanding of each of issuer’s classes of common stock, as of the latest practicable date.
Common Stock, $.10 par value
 
48,949,240
Class
 
Outstanding at July 31, 2017




 
 
 

INDEX
 
 
 
Page No.
PART I.
 
 
 
 
Item 1.
 
 
 
 
 
Consolidated Statements of Income - Three and Nine Months Ended July 31, 2017 and 2016
 
 
 
 
Consolidated Statements of Comprehensive Income (Loss) - Three and Nine Months Ended July 31, 2017 and 2016
 
 
 
 
Consolidated Condensed Balance Sheets - July 31, 2017 and October 31, 2016
 
 
 
 
Consolidated Condensed Statements of Cash Flows - Nine Months Ended July 31, 2017 and 2016
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
PART II.
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 6.
 
 
 
 

2



 
 
 

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Statements of Income
Periods Ended July 31,
(In millions, except for earnings per share)
(Unaudited)
 
Three Months
 
Nine Months
   
2017
 
2016
 
2017
 
2016
Net sales
$
556.0

 
$
514.7

 
$
1,577.5

 
$
1,448.2

Cost of sales
199.8

 
198.1

 
565.1

 
571.1

Gross profit
356.2

 
316.6

 
1,012.4

 
877.1

Selling, general and administrative expense
208.7

 
182.4

 
590.6

 
533.7

Research and development expense
17.5

 
15.9

 
50.6

 
47.4

Amortization of intangibles
17.2

 
15.6

 
50.6

 
46.1

Operating income
112.8

 
102.7

 
320.6

 
249.9

Interest expense
8.3

 
8.0

 
23.3

 
20.9

Other (income) expense, net
(3.2
)
 
1.3

 
(0.1
)
 
2.2

Income before income taxes
107.7

 
93.4

 
297.4

 
226.8

Provision for income taxes
4.1

 
5.2

 
13.1

 
12.4

Net income
103.6

 
88.2

 
284.3

 
214.4

Less: net income attributable to noncontrolling interests

 
0.3

 

 
1.0

Net income attributable to Cooper stockholders
$
103.6

 
$
87.9

 
$
284.3

 
$
213.4

Earnings per share attributable to Cooper stockholders - basic
$
2.12

 
$
1.81

 
$
5.81

 
$
4.41

Earnings per share attributable to Cooper stockholders - diluted
$
2.09

 
$
1.79

 
$
5.74

 
$
4.36

Number of shares used to compute earnings per share:

 

 
 
 
 
Basic
48.9

 
48.6

 
48.9

 
48.4

Diluted
49.6

 
49.0

 
49.5

 
48.9

See accompanying notes.

3



 
 
 

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)
Periods Ended July 31,
(In millions)
(Unaudited)
 
Three Months
 
Nine Months
  
2017
 
2016
 
2017
 
2016
Net income
103.6

 
88.2

 
$
284.3

 
$
214.4

Other comprehensive income (loss):

 

 

 

Foreign currency translation adjustment
38.3

 
(126.8
)
 
104.8

 
(188.3
)
Comprehensive income (loss)
141.9

 
(38.6
)
 
389.1

 
26.1

Less: comprehensive income attributable to noncontrolling interests

 
0.3

 

 
1.0

Comprehensive income (loss) attributable to Cooper stockholders
141.9

 
(38.9
)
 
$
389.1

 
$
25.1

See accompanying notes.

4



 
 
 


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Balance Sheets
(In millions, unaudited)
 
July 31, 2017
 
October 31, 2016
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
46.0

 
$
100.8

Trade accounts receivable, net of allowance for doubtful accounts of $10.0 at July 31, 2017 and $8.5 at October 31, 2016
335.9

 
291.4

Inventories
453.9

 
417.7

Deferred tax assets (1)

 
49.7

Prepaid expense and other current assets
96.3

 
77.5

Total current assets
932.1

 
937.1

Property, plant and equipment, at cost
1,718.5

 
1,603.2

Less: accumulated depreciation and amortization
823.6

 
725.5

 
894.9

 
877.7

Goodwill
2,333.6

 
2,164.7

Other intangibles, net
487.9

 
441.1

Deferred tax assets (1)
66.1

 
6.1

Other assets
68.2

 
51.9

 
$
4,782.8

 
$
4,478.6

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Short-term debt
$
33.4

 
$
226.3

Accounts payable
112.2

 
107.4

Employee compensation and benefits
75.5

 
77.7

Other current liabilities
150.1

 
131.8

Total current liabilities
371.2

 
543.2

Long-term debt
1,180.0

 
1,107.4

Deferred tax liabilities (1)
30.9

 
37.5

Accrued pension liability and other
107.4

 
94.6

Total liabilities
1,689.5

 
1,782.7

Commitments and contingencies

 

Stockholders’ equity:

 
 
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding

 

Common stock, 10 cents par value, shares authorized: 120.0; issued 52.4 at July 31, 2017 and 52.1 at October 31, 2016
5.2

 
5.2

Additional paid-in capital
1,516.9

 
1,494.0

Accumulated other comprehensive loss
(384.8
)
 
(489.6
)
Retained earnings
2,345.6

 
2,046.3

Treasury stock at cost: 3.4 shares at July 31, 2017 and 3.3 shares at October 31, 2016
(389.7
)
 
(360.1
)
Noncontrolling interests
0.1

 
0.1

Stockholders’ equity
3,093.3

 
2,695.9

 
$
4,782.8

 
$
4,478.6

(1) Prospective adoption of ASU 2015-17, Balance Sheet Classification of Deferred Taxes. Refer to Note 1.
See accompanying notes.

5



 
 
 

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Statements of Cash Flows
Nine Months Ended July 31,
(In millions)
(Unaudited)
 
2017
 
2016
Cash flows from operating activities:
 
 
 
Net income
$
284.3

 
$
214.4

Depreciation and amortization
141.2

 
150.9

Decrease in operating capital
(58.7
)
 
(54.6
)
Other non-cash items
27.8

 
5.6

Net cash provided by operating activities
394.6

 
316.3

Cash flows from investing activities:
 
 
 
Purchases of property, plant and equipment
(95.4
)
 
(117.4
)
Acquisitions of businesses, net of cash acquired, and other
(197.0
)
 
(251.3
)
Net cash used in investing activities
(292.4
)
 
(368.7
)
Cash flows from financing activities:
 
 
 
Proceeds from long-term debt
1,064.8

 
1,514.3

Repayments of long-term debt
(984.6
)
 
(1,397.4
)
Net repayments of short-term debt
(202.3
)
 
(23.0
)
Repurchase of common stock
(29.5
)
 

Net (payments) proceeds related to share-based compensation awards
(5.6
)
 
6.2

Excess tax benefit from share-based compensation awards (1)

 
11.8

Dividends on common stock
(1.5
)
 
(1.5
)
Debt acquisition costs

 
(12.5
)
Distributions to noncontrolling interests

 
(0.7
)
Payment of contingent consideration
(4.3
)
 

Proceeds from construction allowance
2.1

 
4.3

Net cash (used in) provided by financing activities
(160.9
)
 
101.5

Effect of exchange rate changes on cash and cash equivalents
3.9

 
(2.9
)
Net (decrease) increase in cash and cash equivalents
(54.8
)
 
46.2

Cash and cash equivalents - beginning of period
100.8

 
16.4

Cash and cash equivalents - end of period
$
46.0

 
$
62.6

(1) Adoption of ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting, excess tax benefits classified as operating activity on a prospective basis. Refer to Note 1.

See accompanying notes.

6

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)


Note 1. General
The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life Company TM with a focus on delivering shareholder value. Cooper operates through our business units, CooperVision and CooperSurgical.
CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.
CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to families.
The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper’s consolidated condensed financial position at July 31, 2017 and October 31, 2016 , the consolidated results of its operations for the three and nine months ended July 31, 2017 and 2016 and its consolidated condensed cash flows for the nine months ended July 31, 2017 and 2016 . Most of these adjustments are normal and recurring. However, certain adjustments associated with acquisitions are of a nonrecurring nature. Readers should not assume that the results reported here either indicate or guarantee future performance.
During interim periods, we follow the accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 . Please refer to this when reviewing this Quarterly Report on Form 10-Q.
Management estimates and judgments are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). We believe that the critical accounting policies listed below address the more significant estimates required of Management when preparing our consolidated financial statements in accordance with GAAP. We consider an accounting estimate critical if changes in the estimate may have a material impact on our financial condition or results of operations. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are:
Revenue recognition
Net realizable value of inventory
Valuation of goodwill
Business combinations
Income taxes
Share-based compensation
During the first nine months of fiscal 2017 , there were no significant changes in our estimates and critical accounting policies except for the accounting pronouncements that were recently adopted which are discussed below. Please refer to Note 1. Summary of Significant Accounting Policies of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 , for a more complete discussion of our estimates and critical accounting policies.
During the first quarter of fiscal 2017, the Company identified and recorded an amount of $4.1 million , net of income tax expense, to reflect a net cumulative decrease to retained earnings as of the opening balance sheet for the fiscal year ended October 31, 2016 and a corresponding net increase in other current liabilities and deferred tax asset, all associated with an understatement of accruals for rebates in prior years. Accordingly, the Company has not revised income statements or cash flows of any periods as the impact to all periods is minimal since the understated rebates liability was accumulated primarily prior to fiscal 2014. Based upon evaluation and consideration of provisions under ASC 250, Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No.99, Materiality ,

7

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

we determined that the impact is not material to our prior year's consolidated financial statements. However, we have revised our prior year Balance Sheet at October 31, 2016 in this Quarterly Report on Form 10-Q to reflect this adjustment.
Accounting Pronouncements Issued Not Yet Adopted

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. We are currently evaluating the impact of ASU 2017-07, which is effective for the Company in our fiscal year and interim periods beginning November 1, 2018.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal 2019 and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. Early adoption is permitted.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-01 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We are currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018.
Accounting Pronouncements Recently Adopted

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. Under the amendments in this update, an entity should perform goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the carrying amount which exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company has elected to early adopt ASU 2017-04 effective in the third quarter of fiscal 2017. The adoption has no material impact on the Company's reported financial results.

In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company has elected to early adopt ASU 2017-01 effective in the second quarter of fiscal 2017. The adoption has no material impact for the Company.


8

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

In March 2016, the FASB issued ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , to improve the accounting for share-based payments to employees. ASU 2016-09 requires excess tax benefits (windfall tax benefits) and tax deficiencies (shortfalls) to be recognized as income tax expense or benefit in the income statement when awards vest or are settled. Companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The standard also allows for additional employee tax withholding on the exercise or release of awards, without triggering liability classification of the award. Finally, the update allows an accounting policy election for the treatment of forfeitures of stock based awards. Companies can elect to continue to estimate forfeitures expected to occur, or account for forfeitures as they occur. The Company has elected to early adopt ASU 2016-09 effective November 1, 2016.

Accordingly, the Company recognized $17.9 million in deferred tax assets associated with excess tax benefits not previously recognized in deferred taxes as a cumulative-effect adjustment to retained earnings at November 1, 2016. The Company also recognized excess tax benefits as a discrete income tax benefit of $13.4 million during the first nine months of fiscal 2017, which is classified as an operating activity in the Consolidated Statements of Cash Flows on a prospective basis. The Company elected to continue to estimate forfeitures that are expected to occur when estimating the amount of compensation expense to record in each accounting period.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which requires entities to present all deferred tax assets and liabilities as noncurrent in the Balance Sheet. ASU 2015-17 can be early adopted for any period that has not been issued on a prospective or retrospective basis. The Company elected to early adopt this guidance on a prospective basis for the quarter ended January 31, 2017. No prior periods were retrospectively adjusted.

Note 2. Acquisitions

Fiscal Year 2017
On June 30, 2017 , we completed the acquisition of Grand Vista LLC, a long-standing distribution partner in Russia . The fair value of the consideration transferred for the acquisition was approximately $23.7 million in cash, $23.1 million net of cash acquired. Our preliminary allocation of the fair value of the purchase price includes $14.9 million for customer relationships; $10.3 million in goodwill; and $1.5 million in identifiable net liabilities. We are in the process of finalizing information related to assets, liabilities and the corresponding effect on goodwill.
On November 4, 2016 , we completed the acquisition of Wallace, the in-vitro fertilization (IVF) segment of Smiths Medical International, Ltd., a division of Smiths Group plc. The fair value of the consideration transferred for the acquisition was approximately $167.4 million in cash. Our allocation of the fair value of the purchase price includes $72.2 million in identifiable intangible assets, consisting of $66.5 million for technology, $3.2 million for trade names and $2.5 million for customer relationships; $94.8 million in goodwill; and $0.4 million in identifiable net assets.
Fiscal Year 2016

On May 31, 2016 we completed the acquisition of Reprogenetics UK, a UK based genetics laboratory specializing in service offerings of preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) used during the IVF process. The fair value of the consideration transferred for the acquisition was approximately $11.7 million , $11.4 million net of cash acquired. Our allocation of the fair value of the purchase price includes $6.3 million in identifiable intangible assets, consisting of $5.1 million for customer relationships and $1.2 million for trade names; $5.6 million in goodwill; and $0.2 million in identifiable net liabilities.
On May 25, 2016 , we completed the acquisition of Recombine Inc., a U.S. based clinical genetic testing company specializing in carrier screening. The fair value of the consideration transferred for the acquisition was approximately $84.4 million , $84.0 million net of cash acquired. Our allocation of the fair value of the purchase price includes $30.0

9

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

million in identifiable intangible assets, consisting of $23.1 million for technology, $2.4 million for customer relationships and $4.5 million for trade names; $65.0 million in goodwill; and $10.5 million in identifiable net liabilities.
On May 4, 2016 , we completed the acquisition of Kivex Biotec A/S (K-Systems), a Danish manufacturer and distributor of equipment for IVF clinics. The fair value of the consideration transferred for the acquisition was approximately $11.7 million , $11.5 million net of cash acquired. Our allocation of the fair value of the purchase price includes $5.4 million in identifiable intangible assets, consisting of $3.6 million for Technology, $1.0 million for trade names and $0.8 million for customer relationships; $5.6 million in goodwill; and $0.7 million in identifiable net tangible assets.
On March 31, 2016 we completed the acquisition of Genesis Genetics Inc., a U.S. based genetics laboratory specializing in preimplantation genetic screening and preimplantation genetic diagnosis used during the IVF process. The fair value of the consideration transferred for the acquisition was approximately $61.1 million in cash, $60.5 million net of cash acquired. Our allocation of the fair value of the purchase price includes $28.6 million in identifiable intangible assets, consisting of $25.2 million for customer relationships and $3.4 million for trade names; $28.7 million in goodwill; and $3.8 million in identifiable net tangible assets.

On February 8, 2016 , we completed the acquisition of The Pipette Company, an Australian manufacturer and distributor of micro pipettes for the Assisted Reproductive Technology market. The fair value of the consideration transferred for the acquisition was approximately $20.2 million in cash, $19.6 million net of cash acquired. Our allocation of the fair value of the purchase price includes $5.6 million in identifiable intangible assets, consisting of $5.2 million for customer relationships and $0.4 million for trade names; $15.0 million in goodwill; and $0.4 million in identifiable net liabilities.
On December 17, 2015 , we completed the acquisition of Research Instruments Limited, a UK manufacturer and supplier of IVF medical devices and systems. The fair value of the consideration transferred for the acquisition was approximately $53.6 million in cash, $50.0 million net of cash acquired. Our allocation of the fair value of the purchase price includes $10.3 million in identifiable intangible assets, consisting of $6.2 million for developed technology, $2.2 million of trade names and $1.9 million for customer relationships; $35.8 million in goodwill; and $7.6 million in identifiable net tangible assets.

We believe these acquisitions strengthen CooperVision's business through the addition of new or complementary lens products and strengthen CooperSurgical's business through the addition of new or complementary products and services within IVF and our genetic testing platform.

The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our consolidated results of operations.

Note 3. Restructuring and Integration Costs

2014 Sauflon Integration Plan
During the fourth quarter of fiscal 2014 and in connection with the Sauflon acquisition, our CooperVision business unit initiated restructuring and integration activities to optimize operational synergies of the combined companies. These activities include product and equipment rationalization, workforce reductions and consolidation of duplicative facilities. At October 31, 2016 , our activities related to this restructuring and integration plan were essentially complete. The total restructuring costs under this plan were $148.3 million . There were no charges related to the 2014 Sauflon Integration Plan in the first nine months of fiscal 2017.

In the three and nine month periods ended July 31, 2016, we recorded in cost of sales $8.7 million and $23.5 million of expense, respectively, arising from production-related asset disposals and accelerated depreciation on equipment, primarily related to our hydrogel lenses, based on our review of products, materials and manufacturing processes of Sauflon. We recorded in cost of sales, employee termination costs of $0.4 million and $0.9 million in the three and nine month periods ended July 31, 2016, respectively. We recorded $0.1 million of employee termination costs and $0.2 million for lease termination costs in selling, general and administrative expense in the nine months ended July 31, 2016. We also recorded in research and development expense $0.1 million of employee termination costs in the nine

10

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

months ended July 31, 2016. In addition, CooperVision incurred $10.0 million of integration costs included in operating expenses in the nine months ended July 31, 2016, respectively. CooperVision did not incur integration costs in the first nine months of fiscal 2017.

A summary of the cumulative total restructuring costs by major component recognized at October 31, 2016 , is as follows:
(In millions)
Employee-related
 
Facilities-related
 
Product Rationalization
 
Total
Cumulative amounts incurred as of October 31, 2016
$
17.8

 
$
1.1

 
$
129.4

 
$
148.3


The following table summarizes the restructuring activities by major component for the fiscal year ended October 31, 2016 and the nine months ended July 31, 2017 :
(In millions)
Employee-related
 
Facilities-related
 
Product Rationalization
 
Total
 
 
 
 
 
 
 
 
Balance at October 31, 2015
$
8.6

 
$
0.3

 
$

 
$
8.9

Additions during fiscal 2016

 
0.2

 
56.4

 
56.6

Payments during the fiscal year
(5.2
)
 
(0.2
)
 

 
(5.4
)
Non-cash adjustments (a) (b)
(0.6
)
 

 
(56.4
)
 
(57.0
)
Balance at October 31, 2016
$
2.8

 
$
0.3

 
$

 
$
3.1

Payments during the nine months ended July 31, 2017
(1.5
)
 

 

 
(1.5
)
Non-cash adjustments (a)
(0.7
)
 
(0.3
)
 

 
(1.0
)
Balance at July 31, 2017
$
0.6

 
$

 
$

 
$
0.6

(a) Represent adjustments for currency translation and accrual releases for employee and facilities-related.
(b) Represents equipment disposals, inventory write-offs and accelerated depreciation for product rationalization.

Note 4. Inventories
(In millions)
July 31, 2017
 
October 31, 2016
Raw materials
104.7

 
86.0

Work-in-process
15.1

 
12.6

Finished goods
334.1

 
319.1

 
453.9

 
417.7

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

11

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Note 5. Intangible Assets

Goodwill
(In millions)
CooperVision
 
CooperSurgical
 
Total
Balance at October 31, 2015
$
1,827.6

 
$
369.5

 
$
2,197.1

Net additions during the year ended October 31, 2016
9.1

 
156.9

 
166.0

Translation
(190.3
)
 
(8.1
)
 
(198.4
)
Balance at October 31, 2016
1,646.4

 
518.3

 
2,164.7

Net additions during the nine months ended July 31, 2017
10.3

 
94.4

 
104.7

Translation
56.6

 
7.6

 
64.2

Balance at July 31, 2017
$
1,713.3

 
$
620.3

 
$
2,333.6


We performed our annual impairment assessment in our third quarter of fiscal 2017 and 2016, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards.

In the third quarter of fiscal 2017, we adopted ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment where FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. We performed a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the carrying amount which exceeds the reporting unit's fair value. A reporting unit is the level of reporting at which goodwill is tested for impairment. Our reporting units are the same as our business segments - CooperVision and CooperSurgical - reflecting the way that we manage our business. Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or future downturn in our business, or a future annual goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets, stockholders' equity and financial condition.


12

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Other Intangible Assets
 
At July 31, 2017
 
At October 31, 2016
 
 
(In millions)
Gross Carrying
Amount
 
Accumulated
Amortization
& Translation
 
Gross Carrying
Amount
 
Accumulated
Amortization
& Translation
 
Weighted Average Amortization Period
 
 
 
 
 
 
 
 
 
(In years)
Trademarks
$
40.7

 
$
9.4

 
$
36.6

 
$
6.8

 
12
Technology
423.5

 
164.7

 
354.8

 
139.3

 
11
Customer relationships
310.3

 
139.3

 
285.7

 
121.9

 
13
License and distribution rights and other
68.9

 
42.1

 
65.8

 
33.8

 
9
 
843.4

 
$
355.5

 
742.9

 
$
301.8

 
12
Less: accumulated amortization and translation
355.5

 
 
 
301.8

 
 
 
 
Other intangible assets, net
$
487.9

 
 
 
$
441.1

 
 
 
 
We estimate that amortization expense for our existing other intangible assets at July 31, 2017 , will be $67.7 million in fiscal 2017, $66.3 million in fiscal 2018, $63.9 million in fiscal 2019, $53.9 million in fiscal 2020 and $52.4 million in fiscal 2021.
Note 6. Debt
(In millions)
July 31, 2017
 
October 31, 2016
Short-term:
 
 
 
Overdraft and other credit facilities
$
33.4

 
$
17.1

Current portion of long-term debt

 
210.7

Less unamortized debt issuance cost on term loans

 
(1.5
)
 
$
33.4

 
$
226.3

Long term:
 
 
 
Credit Agreement
$
354.0

 
$

Term loans
830.0

 
1,111.2

Other
0.2

 
0.2

Less unamortized debt issuance cost on term loans
(4.2
)
 
(4.0
)
 
$
1,180.0

 
$
1,107.4


Revolving Credit and Term Loan Agreement on March 1, 2016 (2016 Credit Agreement)
On March 1, 2016 , we entered into a new Revolving Credit and Term Loan Agreement (2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion and a term loan facility in an aggregate principal amount of $830.0 million , each of which, unless terminated earlier, mature on March 1, 2021 . In addition, we have the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $750.0 million , subject to the discretionary participation of the lenders.


13

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between  0.00% and  0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement.

We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the revolving credit facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement.

The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain total leverage ratio and interest coverage ratio, each as defined in the 2016 Credit Agreement:
Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.
Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00 .
At July 31, 2017 , we were in compliance with the Interest Coverage Ratio at 24.08 and the Total Leverage Ratio at 1.70 .
At July 31, 2017 , we had $830.0 million outstanding under the Term Loan and $645.7 million available under the Revolving Credit Agreement.
Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details.
$700.0 million Term Loan and $300 million Term Loan

On August 4, 2014 , we entered into a three -year, $700.0 million , senior unsecured term loan agreement by and among the Company, the lenders party thereto and KeyBank National Association as administrative agent (as subsequently amended, the 2014 Term Loan Agreement) with a maturity date of August 4, 2017 . In August 2014, we utilized this facility to fund the acquisition of Sauflon, as well as to provide working capital and for general corporate purposes. We repaid $493.0 million of the outstanding balance in fiscal 2016 and fully repaid the remaining outstanding balance of $207.0 million in the second quarter of fiscal 2017 using the funds from the 2016 Credit Agreement, as well as from cash provided by operations.

At July 31, 2017 , we had no outstanding balance under the 2014 Term Loan.

On September 12, 2013 , the Company entered into a five -year, $300.0 million , senior unsecured term loan agreement by and among the Company; the lenders party thereto and KeyBank National Association, as administrative agent (as subsequently amended, the 2013 Term Loan Agreement), with a maturity date of September 12, 2018 , subject to amortization of principal of 5% per annum payable quarterly beginning October 31, 2016 , with the balance payable at maturity. In fiscal 2016, we repaid $15.0 million of the outstanding balance and fully repaid the remaining outstanding balance of $285.0 million in May 2017 using the funds from the 2016 Credit Agreement.

At July 31, 2017 , we had no outstanding balance under the 2013 Term Loan.

Amounts outstanding under the 2014 and 2013 Term Loan Agreements (Term Loan Agreements) bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the Term Loan Agreements), plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans and between 0.75% and 1.50% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the Term Loan Agreements.


14

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

These Term Loan Agreements contain customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the agreements, consistent with the 2016 Credit Agreement discussed above.

Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details.
Note 7. Income Taxes
Our effective tax rate (ETR) (provision for income taxes divided by pretax income) for the first nine months of fiscal 2017 was 4.4% . Our year-to-date results reflect the projected fiscal year ETR, plus any discrete items. The ETR used to record the provision for income taxes for the first nine months of fiscal 2016 was 5.4% . The decrease in the effective tax rate in the first nine months of fiscal 2017 reflects a shift in our geographic mix of income as well as the benefit from adopting ASU 2016-09 (Excess tax benefit from share-based compensation).
We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. At November 1, 2016, Cooper had unrecognized tax benefits of $39.9 million , of which, if recognized, $29.7 million would impact our ETR. For the first nine months of fiscal 2017, there were no material changes to the total amount of unrecognized tax benefits.
We have accrued $3.7 million of interest and penalties as of November 1, 2016. It is our policy to recognize the items of interest and penalties directly related to income taxes as additional income tax expense.
Included in the balance of unrecognized tax benefits at November 1, 2016, is $1.6 million related to tax positions for which it is reasonably possible that the total amounts could significantly change during the next twelve months. This amount represents a decrease in unrecognized tax benefits related to expiring statutes in various jurisdictions worldwide and relates primarily to transfer pricing matters.
At July 31, 2017 , the tax years for which Cooper remains subject to United States Federal income tax assessment upon examination are 2014 through 2016. Cooper remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2013 through 2016.

Note 8. Earnings Per Share
Periods Ended July 31,
Three Months
 
Nine Months
(In millions, except per share amounts)
2017
 
2016
 
2017
 
2016
Net income attributable to Cooper stockholders
$
103.6

 
$
87.9

 
$
284.3

 
$
213.4

Basic:
 
 
 
 
 
 
 
Weighted average common shares
48.9

 
48.6

 
48.9

 
48.4

Basic earnings per common share attributable to Cooper stockholders
$
2.12

 
$
1.81

 
$
5.81

 
$
4.41

Diluted:

 

 
 
 
 
Weighted average common shares
48.9

 
48.6

 
48.9

 
48.4

Effect of potential dilutive common shares
0.7

 
0.4

 
0.6

 
0.5

Diluted weighted average common shares
49.6

 
49.0

 
49.5

 
48.9

Diluted earnings per common share attributable to Cooper stockholders
$
2.09

 
$
1.79

 
$
5.74

 
$
4.36


15

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:
Periods Ended July 31,
Three Months
 
Nine Months
(In thousands, except exercise prices)
2017
 
2016
 
2017
 
2016
Number of stock option shares excluded

 
49

 
192

 
418

Range of exercise prices
$

 
$
162.28

 
$
175.31

 
$131.60-$162.69

Numbers of restricted stock units excluded
2

 
1

 
3

 
3


Note 9. Share-Based Compensation Plans
Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2016 . The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:
Periods Ended July 31,
Three Months
 
Nine Months
(In millions)
2017
 
2016
 
2017
 
2016
Selling, general and administrative expense
$
7.7

 
$
6.4

 
$
24.9

 
$
19.2

Cost of sales
(0.1
)
 
0.7

 
1.9

 
1.8

Research and development expense
0.3

 
0.3

 
0.9

 
0.9

Total share-based compensation expense
$
7.9

 
$
7.4

 
$
27.7

 
$
21.9

Related income tax benefit
$
2.6

 
$
2.2

 
$
8.5

 
$
6.5

We capitalized share-based compensation expense as part of the cost of inventory in the amounts of $0.8 million and $2.8 million during the three and nine months ended July 31, 2017 , respectively; and $0.7 million and $1.8 million during the three and nine months ended July 31, 2016 , respectively. In the third quarter of fiscal 2017, there was an adjustment to cost of sales of $0.9 million to increase share-based compensation capitalized in inventory.
Note 10. Stockholders’ Equity
Analysis of Changes in Accumulated Other Comprehensive Income (Loss):
(In millions)
Foreign Currency Translation Adjustment
 
Minimum Pension Liability
 
Total
Balance at October 31, 2015
$
(171.8
)
 
$
(19.8
)
 
$
(191.6
)
Gross change in value during the year ended October 31, 2016
(289.6
)
 
(13.7
)
 
(303.3
)
Tax effect for the period

 
5.3

 
5.3

Balance at October 31, 2016
$
(461.4
)
 
$
(28.2
)
 
$
(489.6
)
Gross change in value during the nine months ended July 31, 2017
104.8

 

 
104.8

Balance at July 31, 2017
$
(356.6
)
 
$
(28.2
)
 
$
(384.8
)
Share Repurchases
In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company’s common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the

16

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

time and may be made from time to time as permitted by securities laws and other legal requirements. We did not repurchase shares in the third quarter of fiscal 2017. During the second quarter of fiscal 2017, we repurchased 150 thousand shares of our common stock for $29.5 million at an average price of $196.82 . At July 31, 2017 , $589.0 million remains authorized for repurchase under the program. We did not repurchase shares during the first nine months of fiscal 2016.
Dividends
We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 9, 2017, to stockholders of record on January 23, 2017 . We paid another semiannual dividend of approximately $1.5 million or 3 cents per share on August 7, 2017 , to stockholders of record on July 21, 2017 .


Note 11. Fair Value Measurements
At July 31, 2017 and October 31, 2016 , the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms.
Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
We believe that the balances of our revolving credit agreement and term loans approximated their fair values at July 31, 2017 and October 31, 2016 and are categorized as Level 2 of the fair value hierarchy.

Note 12. Employee Benefits
Cooper’s Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.
Our results of operations for the three and nine months ended July 31, 2017 and 2016 reflect the following components of net periodic pension costs:

17

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Periods Ended July 31,
Three Months
 
Nine Months
(In millions)
2017
 
2016
 
2017
 
2016
Service cost
$
2.5

 
$
2.3

 
$
7.5

 
$
6.9

Interest cost
1.1

 
1.2

 
3.3

 
3.7

Expected return on plan assets
(1.8
)
 
(1.6
)
 
(5.4
)
 
(4.9
)
Recognized net actuarial loss
0.7

 
0.4

 
2.1

 
1.2

Net periodic pension cost
$
2.5

 
$
2.3

 
$
7.5

 
$
6.9


We contributed $5.0 million to the Plan in the first nine months of fiscal 2017, and expect to contribute an additional $5.0 million during the remainder of fiscal 2017. We contributed $5.0 million to the Plan in the first nine months of fiscal 2016. The expected rate of return on plan assets for determining net periodic pension cost is 8% .


Note 13. Contingencies

Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. CooperVision and the other defendants jointly filed a motion to dismiss the complaints in December 2015. In June 2016, the motion to dismiss with respect to claims brought under the Maryland Consumer Protection Act was granted, but the motion to dismiss with respect to claims brought under Section 1 of the Sherman Act and other state laws was denied. The actions currently are in discovery. In March 2017, the plaintiffs filed a motion for class certification. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision, subject to Court approval of the settlement. The Company has recorded a settlement accrual of $3.0 million for the third quarter fiscal ended July 31, 2017.

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. Legal fees are recognized as incurred.

Note 14. Business Segment Information
Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.
Total assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.
Segment information:

18

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Periods Ended July 31,
Three Months
 
Nine Months
(In millions)
2017
 
2016
 
2017
 
2016
CooperVision net sales by category:
 
 
 
 
 
 
 
Toric lens
$
138.3

 
$
126.1

 
$
390.8

 
$
354.1

Multifocal lens
46.8

 
44.3

 
132.1

 
127.2

Single-use sphere lens
115.8

 
104.3

 
319.5

 
292.7

Non single-use sphere and other
136.4

 
135.2

 
392.6

 
391.5

Total CooperVision net sales
437.3

 
409.9

 
1,235.0

 
1,165.5

CooperSurgical net sales
118.7

 
104.8

 
342.5

 
282.7

Total net sales
$
556.0

 
$
514.7

 
$
1,577.5

 
$
1,448.2

Operating income (loss):
 
 
 
 
 
 
 
CooperVision
$
109.5

 
$
99.4

 
$
308.9

 
$
235.7

CooperSurgical
14.9

 
14.7

 
48.2

 
47.9

Corporate
(11.6
)
 
(11.4
)
 
(36.5
)
 
(33.7
)
Total operating income
112.8

 
102.7

 
320.6

 
249.9

Interest expense
8.3

 
8.0

 
23.3

 
20.9

Other (income) expense, net
(3.2
)
 
1.3

 
(0.1
)
 
2.2

Income before income taxes
$
107.7

 
$
93.4

 
$
297.4

 
$
226.8

(In millions)
July 31, 2017
 
October 31, 2016
Total assets:
 
 
 
CooperVision
$
3,515.8

 
$
3,382.4

CooperSurgical
1,116.2

 
907.1

Corporate
150.8

 
189.1

Total
$
4,782.8

 
$
4,478.6


19

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Geographic information:
Periods Ended July 31,
Three Months
 
Nine Months
(In millions)
2017
 
2016
 
2017
 
2016
Net sales to external customers by country of domicile:
 
 
 
 
 
 
 
United States
$
235.3

 
$
227.8

 
$
694.8

 
$
656.0

Europe
200.6

 
182.8

 
544.5

 
505.8

Rest of world
120.1

 
104.1

 
338.2

 
286.4

Total
$
556.0

 
$
514.7

 
$
1,577.5

 
$
1,448.2

(In millions)
July 31, 2017
 
October 31, 2016
Net property, plant and equipment by country of domicile:
 
 
 
United States
$
467.7

 
$
464.1

Europe
345.4

 
334.4

Rest of world
81.8

 
79.2

Total
$
894.9

 
$
877.7

 

20

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




Note numbers refer to “Notes to Consolidated Condensed Financial Statements” in Item 1. Financial Statements.

Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These include statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including all statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expecting timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like “believes,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are:
Adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items, including but not limited to, the United Kingdom’s election to withdraw from the European Union.
Foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our revenues and/or earnings.
Our indebtedness and associated interest expense, could adversely affect our financial health, prevent us from fulfilling our debt obligations or limit our ability to borrow additional funds.
Changes in tax laws or their interpretation and changes in statutory tax rates, including but not limited to, the United States, the United Kingdom and other countries with proposed changes to tax laws, some of which may affect our taxation of earnings recognized in foreign jurisdictions and/or negatively impact our effective tax rate.
Acquisition-related adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of acquisitions; integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms).
A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to integration of acquisitions, natural disasters, system upgrades or other causes.
A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades.
Disruptions in supplies of raw materials, including but not limited to, components used to manufacture our silicone hydrogel lenses.

21

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




New U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry and the medical device industry.
Compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of third party information, including but not limited to product recalls, warning letters, and data security breaches.
Legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement or other litigation.
Limitations on sales following product introductions due to poor market acceptance.
New competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions.
Reduced sales, loss of customers and costs/expenses related to recalls.
Failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products.
Failure of our customers and end users to obtain adequate coverage and reimbursement from third party payors for our products and services.
The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill and idle manufacturing facilities and equipment.
The success of our research and development activities and other start-up projects.
Dilution to earnings per share from acquisitions or issuing stock.
Changes in accounting principles or estimates.
Environmental risks.
Other events described in our Securities and Exchange Commission filings, including the “Business” and “Risk Factors” sections in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016, as such Risk Factors may be updated in quarterly filings.
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.



22

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




Results of Operations
In this section, we discuss the results of our operations for the third quarter of fiscal 2017 ended July 31, 2017 , and the nine months then ended and compare them with the same periods of fiscal 2016. We discuss our cash flows and current financial condition under “Capital Resources and Liquidity.” Within the tables presented, percentages are calculated based on the underlying whole-dollar amounts and, therefore, may not recalculate from the rounded numbers used for disclosure purposes.
Third Quarter Highlights
Net sales of $556.0 million , up 8% from $514.7 million . CooperVision net sales up 7% to $437.3 million . CooperSurgical net sales up 13% to $118.7 million
Gross profit $356.2 million , up 12% from $316.6 million . Gross margin 64% up from 62%
Operating income $112.8 million , up 10% from $102.7 million . Operating margin 20% , same as prior year period
Diluted earnings per share of $2.09 per share, up 30 cents from $1.79 per share
Cash provided by operations $154.6 million , up from $ 128.9 million

Nine-Month Highlights
Net sales of $ 1,577.5 million , up 9% from $ 1,448.2 million . CooperVision net sales up 6% to $1,235.0 million . CooperSurgical net sales up 21% to $342.5 million
Gross profit $ 1,012.4 million , up 15% from $ 877.1 million . Gross margin 64% up from 61%
Operating income $ 320.6 million , up 28% from $ 249.9 million . Operating margin 20% , up from 17%
Diluted earnings per share of $ 5.74 , up $1.38 from $ 4.36 per share
Cash provided by operations $394.6 million , up from $316.3 million

Outlook

Overall, we remain optimistic about the long-term prospects for the worldwide contact lens and general health care markets. However, events affecting the economy as a whole, including but not limited to the uncertainty and instability of global markets driven by foreign currency volatility, debt concerns, the uncertainty caused by the United Kingdom's intention to withdraw from the European Union, and the trend of consolidation within the health care industry, impact our current performance and continue to represent a risk to our future performance.
CooperVision - We compete in the worldwide contact lens market with our spherical, toric and multifocal contact lenses offered in a variety of materials including using silicone hydrogel Aquaform ® technology and phosphorylcholine technology (PC) Technology™. We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options. CooperVision is focused on greater worldwide market penetration of recently introduced products and we continue to expand our presence in existing and emerging markets, including through acquisitions. Subsequent to the third quarter of fiscal 2017, in August 2017, we acquired Procornea, a Netherlands based manufacturer of specialty contact lenses, this acquisition expands CooperVision's access to myopia (nearsightedness) management markets with new products. In June 2017, we acquired Grand Vista LLC, a Russian distributor of soft contact lenses and in September 2016, we acquired Soflex, an Israeli manufacturer and distributor of soft contact lenses and aftercare solutions.

23

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




Sales of contact lenses utilizing silicone hydrogel materials continue to grow and this material represents about half of the industry's sales. Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability. CooperVision manufactures and markets a wide variety of silicone hydrogel contact lenses within the daily, two-week and monthly modalities along with manufacturing some of these lenses as toric and/or multifocal lenses. These lenses are marketed under a number of different brand names, including but not limited to, Biofinity ® , clariti ® , MyDay ® and Avaira ® .
We believe the global market for single-use contact lenses will continue growing and our single-use silicone hydrogel products represent an opportunity for our business. Our clariti 1day brand provides the only single-use silicone hydrogel lenses in the marketplace with a complete line of spherical, toric and multifocal contact lenses. We forecast increasing aggregate demand for clariti 1day and MyDay products, as well as future single-use products.
CooperSurgical - Our CooperSurgical business competes in the general health care market with a focus on advancing the health of families through a diversified portfolio of products and services focusing on women's health, fertility and diagnostics. CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model. CooperSurgical product sales are categorized based on the point of health care delivery including products used in medical office and surgical procedures primarily by obstetricians and gynecologists (ob/gyns) that represented 45% of CooperSurgical's net sales in the third quarter of fiscal 2017 compared to 50% in the prior year period. CooperSurgical's remaining sales are specialized products and services that largely target the in vitro fertilization (IVF) process used in fertility that now represent 55% of CooperSurgical's net sales up from 50% in the prior year period. This change in product mix is attributed to recent acquisitions discussed below.
We have continued to invest in CooperSurgical's business through the acquisition of companies and product lines for new or complementary products and services for the IVF process. In our first quarter of fiscal 2017, we acquired Wallace, the IVF segment of Smiths Medical International Ltd for $167.4 million.
In fiscal 2016, we acquired Recombine Inc., Reprogenetics UK and Genesis Genetics Inc., which compete in service offerings of carrier screening, preimplantation genetic screening (PGS) and/or preimplantation genetic diagnosis (PGD) used during the IVF process, and we also acquired Kivex Biotec A/S, The Pipette Company and Research Instruments, who are manufacturers and distributors of IVF medical devices, systems and/or equipment. Refer to Note 2. Acquisitions and our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details. We intend to continue investing in CooperSurgical's business with the goal of expanding our integrated solutions model within the areas of health care, fertility and diagnostics.

Capital Resources - At July 31, 2017 , we had $46.0 million in cash, primarily outside the United States, and $ 645.7 million available under our syndicated revolving credit agreement. The $ 830.0 million term loan entered on March 1, 2016 remains outstanding at July 31, 2017 . In the second quarter of fiscal 2017, we used funds from operations and from our revolving credit agreement to fully repay the remaining $207.0 million outstanding from the $700.0 million term loan originally entered into on August 4, 2014 and there is no outstanding balance at July 31, 2017. In the third quarter of fiscal 2017, we fully repaid the remaining $ 285.0 million outstanding from the $ 300.0 million term loan originally entered into on September 12, 2013 using the funds from the 2016 Credit Agreement and there is no outstanding balance at July 31, 2017.

On March 1, 2016, we entered into a syndicated revolving Credit and Term Loan Agreement with Keybank as administrative agent. This agreement, maturing on March 1, 2021, replaced our previous revolving Credit Agreement, entered into on January, 12, 2011 and provides for a multi-currency revolving credit facility in an aggregate principal amount of $1.0 billion and a term loan facility in the aggregate principal amount of $830.0 million. We used funds from the new term loan to repay outstanding amounts under the previous Credit Agreement, to repay our other outstanding term loans and for general corporate purposes. See Note 6. Debt for additional information.

We believe our cash and cash equivalents, cash flow from operating activities and borrowing capacity under our credit facilities will fund operations both in the next 12 months and in the longer term. To the extent additional funds are necessary to meet our liquidity needs such as that for acquisitions, share repurchases, cash dividends or other activities as we execute our business strategy, we anticipate that additional funds will be obtained through the incurrence of

24

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




additional indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all.

Selected Statistical Information – Percentage of Sales and Growth
 
 
Three Months
 
Nine Months
 
 
Percentage of Sales
 
2017 vs 2016 % Change
 
Percentage of Sales
 
2017 vs 2016 % Change
Periods Ended July 31,
 
2017
 
2016
 
 
2017
 
2016
 
Net sales
 
100
%
 
100
%
 
8
%
 
100
%
 
100
%
 
9
 %
Cost of sales
 
36
%
 
38
%
 
1
%
 
36
%
 
39
%
 
(1
)%
Gross profit
 
64
%
 
62
%
 
12
%
 
64
%
 
61
%
 
15
 %
Selling, general and administrative expense
 
38
%
 
35
%
 
14
%
 
37
%
 
37
%
 
11
 %
Research and development expense
 
3
%
 
3
%
 
9
%
 
3
%
 
3
%
 
7
 %
Amortization of intangibles
 
3
%
 
3
%
 
10
%
 
3
%
 
3
%
 
10
 %
Operating income
 
20
%
 
20
%
 
10
%
 
20
%
 
17
%
 
28
 %
Net Sales
Our two business units, CooperVision and CooperSurgical, generate all of our sales. Our consolidated net sales grew by $ 41.2 million or 8% , and $ 129.3 million or 9% , in the three and nine months ended July 31, 2017 , respectively:
Periods Ended July 31,
 
Three Months
 
Nine Months
($ in millions)
2017
 
2016
 
2017 vs 2016 % Change
 
2017
 
2016
 
2017 vs 2016 % Change
CooperVision
 
$
437.3

 
$
409.9

 
7
%
 
$
1,235.0

 
$
1,165.5

 
6
%
CooperSurgical
 
118.7

 
104.8

 
13
%
 
342.5

 
282.7

 
21
%
 
 
$
556.0

 
$
514.7

 
8
%
 
$
1,577.5

 
$
1,448.2

 
9
%

25

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




CooperVision Net Sales
The contact lens market has two major product categories:
Spherical lenses including lenses that correct near- and farsightedness uncomplicated by more complex visual defects.
Toric and multifocal lenses including lenses that, in addition to correcting near- and farsightedness, address more complex visual defects such as astigmatism and presbyopia by adding optical properties of cylinder and axis, which correct for irregularities in the shape of the cornea.
In order to achieve comfortable and healthy contact lens wear, products are sold with recommended replacement schedules, often defined as modalities, with the primary modalities being single-use, two-week and monthly. CooperVision offers spherical, toric, multifocal and toric multifocal lens products in most modalities.
Single-use lenses are designed for daily replacement and frequently replaced lenses are designed for two-week or monthly replacement. Significantly, the market for spherical lenses is growing with value-added spherical lenses to alleviate dry eye symptoms, to reduce eye fatigue from use of digital devices, to add aspherical optical properties, and/or higher oxygen permeable lenses such as silicone hydrogels.

CooperVision’s silicone hydrogel Biofinity brand spherical, toric and multifocal contact lenses, Avaira brand spherical and toric lenses and MyDay brand spherical and toric lenses, are manufactured using proprietary Aquaform technology to increase oxygen transmissibility for longer wear. Our silicone hydrogel clariti brand spherical, toric and multifocal contact lenses are available in monthly and single-use modalities. We believe the clariti single-use silicone hydrogel lens products provide a competitive advantage in approved markets as clariti is the only single-use silicone hydrogel lens available in all vision correction categories - spherical, toric and multifocal.

CooperVision’s Proclear ® brand spherical, toric and multifocal contact lenses, manufactured using PC Technology, help enhance tissue/device compatibility and offer improved lens comfort.

CooperVision Net Sales by Category
Three Months Ended July 31,
 
 
 
 
($ in millions)
 
2017
 
% Net Sales
 
2016
 
% Net Sales
 
2017 vs 2016 % Change
Toric
 
$
138.3

 
32
%
 
$
126.1

 
31
%
 
10
%
Multifocal
 
46.8

 
11
%
 
44.3

 
11
%
 
6
%
Single-use spheres
 
115.8

 
26
%
 
104.3

 
25
%
 
11
%
Non single-use sphere, other
 
136.4

 
31
%
 
135.2

 
33
%
 
1
%
 
 
$
437.3

 
100
%
 
$
409.9

 
100
%
 
7
%

Nine Months Ended July 31,
 
 
 
 
($ in millions)
 
2017
 
% Net Sales
 
2016
 
% Net Sales
 
2017 vs 2016 % Change
Toric
 
$
390.8

 
32
%
 
$
354.1

 
30
%
 
10
%
Multifocal
 
132.1

 
11
%
 
127.2

 
11
%
 
4
%
Single-use spheres
 
319.5

 
26
%
 
292.7

 
25
%
 
9
%
Non single-use sphere, other
 
392.6

 
31
%
 
391.5

 
34
%
 
%
 
 
$
1,235.0

 
100
%
 
$
1,165.5

 
100
%
 
6
%

In the three and nine months ended July 31, 2017, CooperVision's toric and multifocal lenses grew largely through the success of our Biofinity, clariti and MyDay portfolios, offset by declines in older hydrogel products. Single-use sphere

26

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




lenses growth was largely attributable to clariti and MyDay lenses offset by declines in older hydrogel products. Non single-use sphere sales grew largely on sales of Biofinity offset by declines in older hydrogel products. The term "other" products primarily includes lens care, at approximately 2% of net sales, in both the three and nine month periods ended July 31, 2017. Total silicone hydrogel products, including clariti, Biofinity, Avaira and MyDay grew 17% in the three months ended July 31, 2017, representing 66% of net sales compared to 60% in the same period in the prior fiscal year, and grew 16% in the nine months ended July 31, 2017, representing 65% of net sales compared to 59% in the same period in the prior fiscal year.

CooperVision Net Sales by Geography

CooperVision competes in the worldwide soft contact lens market and services three primary regions: the Americas, EMEA (Europe, Middle East and Africa) and Asia Pacific.
Periods Ended July 31,
 
Three Months
 
Nine Months
($ in millions)
 
2017
 
2016
 
2017 vs 2016 % Change
 
2017
 
2016
 
2017 vs 2016 % Change
Americas
 
$
168.7

 
$
166.1

 
2
%
 
$
503.6

 
$
482.6

 
4
%
EMEA
 
179.9

 
162.5

 
11
%
 
477.3

 
456.6

 
5
%
Asia Pacific
 
88.7

 
81.3

 
9
%
 
254.1

 
226.3

 
12
%
 
 
$
437.3

 
$
409.9

 
7
%
 
$
1,235.0

 
$
1,165.5

 
6
%
Americas net sales growth was primarily due to silicone hydrogel lenses including Biofinity, clariti, and MyDay, partially offset by the decrease in sales of older hydrogel products. EMEA net sales growth was due to silicone hydrogel lenses including Biofinity, clariti and MyDay, which was partially offset by weakening foreign currencies, primarily the British pound, compared to the prior year against the United States dollar for the nine-month period and euro, for the first half of the fiscal year. Net sales in the Asia Pacific region grew primarily due to silicone hydrogel lenses, including Biofinity, MyDay and clariti.
CooperVision’s net sales were driven primarily by increases in the volume of lenses sold, including recently introduced silicone hydrogel products. While unit growth and product mix have influenced CooperVision’s net sales, average realized prices by product have not materially influenced sales growth.
CooperSurgical Net Sales
CooperSurgical supplies the market for family health care with a diversified portfolio of products and services for use in surgical and other medical procedures that are performed primarily by obstetricians and gynecologists in hospitals, surgical centers, fertility clinics and in the medical office. Fertility offerings include highly specialized products and services that target the in vitro fertilization (IVF) process with a goal to make fertility treatment safer, more efficient and convenient.
Three Months Ended July 31,
 
 
 
 
 
 
 
 
 
 
($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
Fertility
 
$
65.5

 
55
%
 
$
52.0

 
50
%
 
26
%
Office and surgical products
 
53.2

 
45
%
 
52.8

 
50
%
 
1
%
 
 
$
118.7

 
100
%
 
$
104.8

 
100
%
 
13
%
Nine Months Ended July 31,
 
 
 
 
 
 
 
 
 
 
($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
Fertility
 
$
183.4

 
54
%
 
$
123.5

 
44
%
 
49
 %
Office and surgical products
 
159.1

 
46
%
 
159.2

 
56
%
 
 %
 
 
$
342.5

 
100
%
 
$
282.7

 
100
%
 
21
 %


27

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




The growth in CooperSurgical's net sales of fertility products and services compared to the prior year periods were primarily due to sales of products and services of companies acquired during the first nine months of fiscal 2017. The net sales of medical office and surgical products in the three and nine months ended July 31, 2017 remained relatively flat compared to the prior year periods due to declines in sales of disposable products, partially offset by growth in recently launched products used in surgical procedures. Unit growth and product mix, primarily sales of recently acquired products and services, influenced sales growth.

Cost of Sales/Gross Profit
Gross Profit Percentage of Net Sales
 
Three Months
 
Nine Months
Periods Ended July 31,
2017
 
2016
 
2017
 
2016
CooperVision
 
65
%
 
62
%
 
65
%
 
60
%
CooperSurgical
 
61
%
 
61
%
 
61
%
 
63
%
Consolidated
 
64
%
 
62
%
 
64
%
 
61
%
CooperVision's increases in gross margin in the three and nine months ended July 31, 2017 as compared to the prior year periods are primarily due to the increase in sales of higher margin products including Biofinity and favorable currency impact to CooperVision's cost of sales primarily led by the weakening of British pound compared to the United States dollar. Prior year period's gross margin was also negatively impacted due to product and equipment rationalization costs arising from the Sauflon restructuring and integration activities and facility startup costs for $10.3 million and $30.3 million in the three and nine months ended July 31, 2016, respectively. CooperVision's cost of sales include $2.8 million of product write off costs due to new product transition in Coopervision in the three and nine months ended July 31, 2017 and $0.6 million of facility start up costs in the nine months ended July 31, 2017.
CooperSurgical’s gross margin remained flat in the three-month period ended July 31, 2017 and decreased in the nine months ended July 31, 2017 as compared to the prior year period, primarily due to higher integration costs and the addition of sales of lower margin services from acquisitions. CooperSurgical's cost of sales in fiscal 2017 include $1.3 million and $2.8 million of integration costs in the three and nine months ended July 31, 2017, respectively; and in fiscal 2016 included $0.3 million and $1.6 million of integration costs in the three and nine months ended July 31, 2016, respectively.
Selling, General and Administrative Expense (SGA)
Three Months Ended July 31,
 
 
 
 
 
 
 
 
 
 
($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
CooperVision
 
$
153.2

 
35
%
 
$
132.2

 
32
%
 
16
%
CooperSurgical
 
43.9

 
37
%
 
38.8

 
37
%
 
13
%
Corporate
 
11.6

 
 -

 
11.4

 
 -

 
3
%
 
 
$
208.7

 
38
%
 
$
182.4

 
35
%
 
14
%
Nine Months Ended July 31,
 
 
 
 
 
 
 
 
 
 
($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
CooperVision
 
$
432.3

 
35
%
 
$
398.1

 
34
%
 
9
%
CooperSurgical
 
121.8

 
36
%
 
101.9

 
36
%
 
20
%
Corporate
 
36.5

 
 -

 
33.7

 
 -

 
8
%
 
 
$
590.6

 
37
%
 
$
533.7

 
37
%
 
11
%
The increases in CooperVision's SGA in absolute dollars and as a percentage of sales in the three and nine months ended July 31, 2017 as compared to the prior year periods are due to investments to support our long term objectives,

28

Table of Contents
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations




including increased headcount in sales, marketing and G&A, investments in information technology and higher distribution expenses to support revenue growth. CooperVision's SGA in the three and nine months ended July 31, 2017, include $0.5 million and $1.5 million of acquisition costs and $5.8 million and $8.8 million of legal costs, respectively. Legal costs related to litigation of class action complaints filed against CooperVision and other contact lens manufacturers relating to Unilateral Pricing Policy (UPP), including a settlement accrual of $3.0 million, and state and federal lobbying expenses.
CooperVision's SGA in the prior year period included $0.4 million and $1.8 million of legal costs relating to UPP in the three and nine months ended July 31, 2016, respectively. Prior year period SGA also included $10.0 million of Sauflon restructuring and integration costs in the nine months ended July 31, 2016.
The increases in CooperSurgical's SGA in absolute dollars are primarily due to the inclusion of operating expenses of recently acquired companies and investment in headcount to support growth. CooperSurgical's SGA included $3.7 million and $10.1 million of primarily acquisition and integration expenses from recently acquired companies in the three and nine months ended July 31, 2017, respectively, compared to $2.7 million and $8.9 million in the prior year periods, respectively. CooperSurgical continues to invest in sales activities to promote products and to reach new customers.
The increases in Corporate SGA in absolute dollars for the three and nine months ended as compared to the prior year periods are primarily due to share based compensation related expenses.
Research and Development Expense (R&D)
Three Months Ended July 31,
 
 
 
 
 
 
 
 
 
 

($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
CooperVision
 
$
11.7

 
3
%
 
$
11.5

 
3
%
 
2
%
CooperSurgical
 
5.8

 
5
%
 
4.4

 
4
%
 
27
%
 
 
$
17.5

 
3
%
 
$
15.9

 
3
%
 
9
%
Nine Months Ended July 31,
 
 
 
 
 
 
 
 
 
 

($ in millions)
 
2017
 
% Net
Sales
 
2016
 
% Net
Sales
 
2017 vs 2016 % Change
CooperVision
 
$
34.6

 
3
%
 
$
35.0

 
3
%
 
(1
)%
CooperSurgical
 
16.0

 
5
%
 
12.4

 
4
%
 
28
 %
 
 
$
50.6

 
3
%
 
$
47.4

 
3
%
 
7
 %
The decrease in CooperVision's R&D expenses in absolute dollars in the nine months ended July 31, 2017 compared to the prior year periods are primarily due to reduction in headcount due to synergies from integration activities. CooperVision's R&D activities are primarily focused on the development of contact lenses and manufacturing improvements.
The increases in CooperSurgical's R&D expenses in absolute dollars in the three and nine months ended July 31, 2017 are primarily due to increased activity to bring newly acquired